Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Online Software Designed to Enhance Target Enrichment Custom Design Process for Next-Generation Sequencing

By BiotechDaily International staff writers
Posted on 04 Jul 2013
A new next-generation sequencing online software’s design algorithm provides an empirically optimized probe database that allows users to obtain and review designs in an automated setting before making the purchase decision.

Roche (Basel, Switzerland) announced the worldwide launch of the NimbleDesign tool, an online software that enables customers to easily design optimized SeqCap EZ Choice Libraries in as little as one hour.

“NimbleDesign is based on years of target enrichment design experience from our bioinformatics experts,” said Thomas Schinecker, president of Roche sequencing solutions. “Following the very positive feedback we received from pilot users in selected regions we are excited to offer this software tool globally now. It marks another step in our ongoing efforts to improve the customer convenience of our target enrichment portfolio.”

The NimbleDesign application enables customers to take full use of Roche’s novel SeqCap EZ library technology, providing more effective finding of single nucleotide polymorphisms (SNPs) and better uniform coverage than many other existing technologies. Furthermore, using the easy-to-use interface, users can develop multiple designs simultaneously with very fast turnaround time. Adding to the customer convenience with the launch of SeqCap EZ reagents earlier in 2013, the NimbleDesign tool additionally streamlines the design workflow and ordering process.

The system is developed for life science research only.

Related Links:
Roche



Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.